Destiny Pharma agrees research pact with Cystic Fibrosis Foundation
The company will assess the potential use of its XF-73 drug in treating people with cystic fibrosis that have contracted methicillin-resistant MRSA
Company
Destiny Pharma PLC
LON:DEST
Destiny Pharma PLC is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
97 stories · page 3 of 5
Destiny Pharma’s XF-73 can enhance two widely used antibiotics, new research suggests
XF-73 improved the performance against MRSA and Pseudomonas aeruginosa
Destiny Pharma starts research into preventive drug for cancer treatment side effect
The research on the medication, called XF-73, will be conducted in the US by Professor Stephen Sonis
Archive
Small Cap Feast - Destiny Pharma, Poolbeg Pharma, and more...
12 May 2022*A corporate client of Hybridan LLPDish of the dayJoiners:No Joiners Today.Leavers:No Leavers Today.What’s cooking in the IPO kitchen?Trade journal, the drinks business, reports that two drinks companies of vastly different sizes
Destiny Pharma names Yuri Martina as new chief medical officer
Recently, Martina was senior vice president and deputy chief medical officer at Grunenthal Group
Destiny Pharma undervalued compared to peers, suggests finnCap
"Phase 3 trial design is due to be finalised in H1 2022, which should catalyse partnering discussions.“
Destiny Pharma expects to make significant progress with late-stage assets
The update was provided alongside the company's full-year results
Destiny Pharma raises £6.45mln for pipeline development
The biotech firm said 12.9mln new shares are set to trade on AIM
Destiny Pharma's lead assets have the potential to generate US$1bn globally each
Destiny Pharma is currently in advanced discussions with commercial partners for both assets
Destiny Pharma raises funds to finance progress towards Phase 3 trials on its two lead assets
The board conceded that the timing of the share issue could have been better given the volatility of current markets but felt it better to bite the bullet rather than wait for a stronger market
Archive
Small Cap Wrap - Serinus Energy, Midwich, Great Western Mining and more...
Great Western Mining 0.13p £4.7m (LON:GWMO) Great Western Mining Corporation PLC, which is exploring and developing gold, silver and copper targets in Nevada, today updates shareholders on its 2022 approved drilling programme.
Destiny Pharma receives the 'positive feedback' from European regulators for phase III trial
Essentially, researchers developing the nasal gel for postoperative infection will have to hit the same end-goal as they did in phase II
Destiny Pharma reports positive results from safety study of novel dermal formulation
"We are very pleased with the encouraging data from our novel XF-73 dermal formulation which is aimed at meeting a clear clinical need in a large market where peak product sales could reach half a billion US dollars," said Destiny Pharma CE
Destiny Pharma unveils positive results for c-difficile treatment as research points to commercial potential
NTCD-M3, which researchers are readying to phase III clinical trials, was the subject to a separate preclinical study by the US Department of Veterans Affairs
Destiny Pharma: Lancet study validates clinical need to fight AMR
More than one million deaths occurred in one year due to bacterial Antimicrobial Resistance (AMR), whcih the company seeks to address with in-trial candidates.
Destiny Pharma making progress towards phase 3 trials
Preclinical work on SPOR-COV, designed to prevent coronavirus infections, is progressing as planned
Destiny Pharma shares study supporting need for XF-73 nasal gel candidate
The study explored the link between Staphylococcus aureus decolonisation and Intensive Care Units infection rates
Destiny Pharma's China partner begins programme to develop new skin infection product
Destiny will have cross-reference rights to the data and so could start a similar skin infection clinical programme in the future
Destiny Pharma to build on progress made by two key assets
The company is blazing a trail in the infection arena and reckons it has two potential blockbuster treatments on its hands
Destiny Pharma publishes more evidence of XF-73 nasal gel's effectiveness
"We are very pleased to announce this additional, positive data from the successful Phase 2b study of XF-73 as a novel drug to reduce the incidence of post-surgical infections such as MRSA."